Lindsey Summers 🎗💛

The Q3 Job Market Report from BioSpace just dropped, and you definitely want to check it out! The life sciences job market is going through some big changes, and keeping up with the latest info is super important for navigating it all. According to the new BioSpace data, there are some challenges but also plenty of opportunities coming up! 🔍 Key Insights from BioSpace's Q3 2024 Report: 1. Decrease in Job Postings:   - There were 21,548 jobs live on BioSpace in Q3 2024.   - This is a 12% decrease from 24,503 jobs in Q3 2023. 2. Increase in Job Competition:   - The job response rate (percentage of people applying after viewing) jumped from 9.8% to 14.8%, a 51% increase year-over-year.   - Notably, from July to September 2024, the response rate surged from 14.5% to 18.4%, a 26.9% increase. 3. Top States for Job Openings:   - California: 3,769 jobs   - Massachusetts: 3,110 jobs   - New Jersey: 2,513 jobs   - Illinois: 2,452 jobs   - New York: 1,717 jobs 4. Impact of Layoffs:   - In Q3 2024, there were 54 rounds of layoffs in biotech and pharma, affecting at least 3,700 employees.   Significant layoffs included:    - FibroGen, Inc.: Let go of 75% of its U.S.-based workforce (~356 people).    - GRAIL: Laid off about 350 employees.    - BioMarin Pharmaceutical Inc.: Cut 225 positions globally.    - Johnson & Johnson & Bayer: Combined layoffs of 288 employees in New Jersey. 💡 What This Means for You: - Increased Competition: With fewer job postings and more professionals in the market, it's crucial to differentiate yourself. - Strategic Job Hunting: According to Carina Clingman, PhD, CEO of Recruitomics Consulting, fall is prime time for job hunting in biotech. Companies aim to fill positions before the budget cycle ends around Thanksgiving. 📈 Emerging Opportunities:  - Johnson & Johnson is investing $2 billion in a new biologics manufacturing plant in Wilson, North Carolina, expected to create 420 new full-time, highly skilled jobs. Construction begins in the first half of 2024.  - Eli Lilly and Company is committing $4.5 billion to build a facility in Lebanon, Indiana, housing research and manufacturing. Set to open in late 2027, it will employ about 400 new engineers, scientists, lab technicians, and operations personnel.  - MassBio's 5-Year Plan: Aiming to create hundreds of new biopharma and life sciences positions in Massachusetts by 2030, focusing on supporting early-stage biotech growth. 🚀 Tips to Stay Ahead: - Update Your Skills: Leverage this time to enhance your expertise and stay competitive. - Network: Engage with industry peers and attend virtual or in-person events. - Stay Informed: Keep an eye on emerging biotech hubs and companies expanding their workforce. - Be Proactive: Tailor your applications and highlight how you can add value in this dynamic environment. Share your experiences or tips below. #Biotech #Pharma #JobMarket #CareerGrowth #LifeSciences

4

Community vs. Academic Research Sites: Which is Right for Your Study? As the clinical research landscape evolves, both community-based and academic research sites are making significant contributions to advancing clinical trials in unique ways: 🔹 Community-Based Sites are excelling in patient diversity, accessibility, and faster startup times, reaching historically underrepresented groups in familiar local settings. 🔹 Academic Institutions remain the go-to for complex studies requiring advanced expertise and specialized equipment. 💡 Choosing the right site type can be the difference between success and setbacks in your trial. In 2024, CROs and sponsors are leveraging hybrid models that combine the strengths of both. The result? Broader patient access, increased efficiency, and the ability to meet new diversity requirements. Ready to discuss which approach fits your study? Let’s connect! #ClinicalResearch #CRO #DiversityInTrials #PatientAccess #ClinicalTrials #ResearchInnovation

5

Learn how we organized and pulled together measurable goals and outcomes by unifying both of our FSP and full-service organizations. https://lnkd.in/gNKAahyQ #clinicaltrials #clinicalresearch

2

The FDA's latest draft guidance on diversity in clinical trials aims to improve the representation of underrepresented populations in clinical research. In their excellent blog post, Lindus Health summarize the key points in the draft. The guidance outlines strategies for increasing enrollment of racial and ethnic minorities, women, older adults, and individuals with disabilities in clinical trials. Key recommendations include setting enrollment targets, using decentralized trial designs, and engaging with community organizations to raise awareness. The guidance emphasizes the importance of ensuring that clinical trial populations reflect the real-world patient population that will use the drug or device. By improving diversity in clinical trials, the FDA hopes to generate data that is more generalizable and relevant to all patients. We say – it’s about time clinical trials be made real patient-centric! thanks Lindus Health for your input. #clinicaltrials #DEI #clinicalresearch

3

Early and effective disease diagnosis and treatment depends on having the right information. Many diagnostic tools are complex and time consuming leading to imprecision. Lab tests drive 70% of today’s medical decisions. 4.5 Billion lab tests are unfulfilled annually in the US. Challenges Include: ▶ Patients can be resistant to invasive testing such as blood draws ▶ Limited access to testing in underserved communities As a result, many diseases are diagnosed at later stages making treatments less effective. At Trace Sensing, we are developing a platform technology capable of impacting several disease categories at early stages, non-invasively and at a lower projected cost. ------ Interested to learn more? Let’s connect! https://lnkd.in/gg3hk4Za

8

After reading Aynsley Szczesniak's post on the NIH Fact Sheets on Women's Health Research, I took a look myself, and some of the statistics are shocking... Normally on 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗪𝗼𝗺𝗲𝗻'𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗗𝗮𝘆, I would spotlight some key trailblazers in the space, but this year will be slightly different🔦 Given the field of Women's Health extends beyond the typical fertility and reproductive space, into cardiovascular care and bone health, it's critical to learn about the conditions that disproportionately affect women (especially racial disparities within that).💻 Some of the statistics that stuck out to me most were: ⚡Of the patients diagnosed with autoimmune disease, 80% are women. ⚡More than 110,000 women per year are diagnosed with a gynecologic cancer, the most common of which are cancers of the uterus, and the most lethal of which is ovarian cancer ⚡Heart disease is the leading cause of death for women in the U.S. ⚡One in five women are at risk for Alzheimer's Disease, compared to 1 in 10 men. ⚡Globally, 54% of people living with HIV are women. Of these, Black women accounted for 54% of new diagnoses among women in the U.S. ⚡An estimated 80% of maternal deaths are preventable. ⚡One in eight women experience perinatal depressive symptoms. #femtech #womenshealth #femtechmetricbio

25

4 Comments